Compare BIO-TECHNE Corp (TECH) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs WD 40 Company — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: BIO-TECHNE Corp is far larger — about 3.5× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| TECH | WDFC | |
|---|---|---|
Market Cap | $11.16B | $3.22B |
Sector | Health | Technology |
52-Week High | $72.12 | $264.91 |
52-Week Low | $43.31 | $187.52 |
Enterprise Value | $11.24B | $3.27B |
Dividend Yield | 0.45% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
WDFC trades at $239.59, down 2.92% today, with a bullish technical signal supported by moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations at $2.33 EPS versus $1.58 expected, driven by strong sales growth. The company maintains solid profitability with a 13.22% net income margin and positive operating cash flow of $87.93 million in 2025, though 2026 projections show slight margin compression.
The outlook is mixed: strong brand moat and consistent cash flow support dividends, but high valuation multiples (P/E 37.5) and analyst caution (71% hold rating) limit near-term upside. Risks include input cost pressures and competitive maintenance markets. Institutional sentiment leans neutral despite recent earnings strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
